Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITA: Pharmacogenetics for Personalized Antidepressant Dosing in Severe Depression
NCT03548675Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2018
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 4, randomised trial in major depressive disorder (MDD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Time to TCA plasma concentration in the therapeutic range at 7 weeks. Started May 2018; status: completed.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03548675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548675.